



Pergamon

Tetrahedron Letters 40 (1999) 9069–9072

TETRAHEDRON  
LETTERS

# The first synthesis of a 2',3'-methano carbocyclic nucleoside<sup>1</sup>

Nobuya Katagiri,\* Yoshitsugu Yamatoya and Minoru Ishikura

Faculty of Pharmaceutical Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido 061-0293, Japan


Received 6 September 1999; revised 29 September 1999; accepted 1 October 1999

## Abstract

A 2',3'-methano carbocyclic nucleoside, 9-(*c*-4-hydroxymethylbicyclo[3.1.0]hex-*r*-2-yl)-9*H*-adenine, has been efficiently synthesized from 2-azabicyclo[2.2.1]hex-5-en-3-one (ABH) in six steps involving 1,3-dipolar cycloaddition, photolysis, and adenine ring construction. © 1999 Elsevier Science Ltd. All rights reserved.

**Keywords:** 2-azabicyclo[2.2.1]hept-5-en-3-one; diazomethane; photolysis; 2',3'-methano carbocyclic nucleoside.


A cyclopropane fused nucleoside, namely methano-nucleoside, has recently attract much attention because of its pharmacological and biological activities. A methano cytidine derivative (**A**) shows antiviral activity.<sup>2</sup> Three types of methano carbocyclic nucleosides (**B**,<sup>3</sup> **C** and **D**) have been synthesized so far. Carbocyclic 4',6'-methano- (**C**) and 1',6'-methano-thymidine (**D**) assume 2'-*exo* and 3'-*exo* conformations, respectively. The nucleoside (**C**) shows significant anti-HSV activity<sup>4</sup> and the oligomer containing **C** has been found to stabilized the duplex.<sup>5</sup> The oligomer consisting of **D** also forms the duplex with the complemental natural oligomer.<sup>6</sup> Quite recently, a cyclopentenyl guanine derivative (**E**: carbovir) has been approved as a drug for the treatment of AIDS.<sup>7</sup> Previously, we reported an efficient synthesis of a precursor of abacavir from 2-azabicyclo[2.2.1]hept-5-en-3-one (ABH) via  $\pi$ -allylpalladium complex.<sup>8</sup> We planned to design a methano derivative (**F**) because a cyclopropane ring as well as a C–C double bond has unsaturated property and therefore **F** can be expected to show anti-HIV activity. In this communication, we now report the first synthesis of racemic **F** from ABH.



Cyclopropane construction was carried out using diazomethane because Simmons–Smith reaction of ABH or its *N*-*t*-Boc derivative (**1**)<sup>9</sup> did not give the desired compound.<sup>10</sup> When **1** was treated with an

\* Corresponding author. Tel: +81 1332 3 1211 ext. 3100; fax: +81 1332 3 1245; e-mail: nobu@hoku-iryu-u.ac.jp


excess of diazomethane–ether solution<sup>11</sup> containing methanol at room temperature overnight, a mixture of **2**<sup>12</sup> and **3**<sup>12</sup> was obtained with the 1:1 ratio in 69% yield concomitant with the formation of **4** (20%). The structure of **2** was confirmed by NOE experiments as shown in Scheme 1. Since **4** did not react with diazomethane under the same conditions, compounds **2** and **3** would be formed by the 1,3-dipolar cycloaddition of **1** with diazomethane followed by solvolysis with methanol. The initial cycloaddition selectively occurred from the *exo* side of **1** in the same manner as the epoxidation of **1** by *m*-CPBA.<sup>13</sup> It is also proved by the latter mentioned reaction. Formation of **4** might be assisted by diazomethane (Scheme 1) because conversion of **1** to **4** did not take place in methanol under neutral condition.<sup>14</sup> Reaction of **1** with diazomethane in the absence of methanol<sup>11</sup> gave a mixture of regioisomers **5**<sup>15</sup> and **6**<sup>15</sup> in 58% and 35% yields, respectively. Determination of the structure of **5** and **6** was made by their conversion to **2** and **3**, respectively. Both compounds were readily converted to the corresponding bicyclo-compound **2** and **3** by methanolysis at room temperature for 10 min. Although **2** and **3** were chromatographically separable, the mixture was used for the following reaction without separation. Thus, a solution of the mixture in acetonitrile was irradiated with high pressure mercury lamp (Pyrex filter) with ice-cooling for 2 h to give a cyclopropane derivative (**7**) in 94% yield. Reduction of **7** with Ca(BH<sub>4</sub>)<sub>2</sub> in ethanol afforded an alcohol (**8**)<sup>16</sup> in 81% yield.



Scheme 1.

A more straightforward synthesis of **8** was examined. Compound (**1**) was treated with diazomethane–ether solution without methanol in the presence of PdCl<sub>2</sub>(PhCN)<sub>2</sub> to give directly a tricyclic compound (**9**) in 41% yield, which was consistent with the compound obtained from the photolysis of **5** and **6** in 42% and 60% respective yields. Compound (**9**) was then submitted to reductive amido cleavage (RAC) reaction using NaBH<sub>4</sub> developed previously by our group<sup>17</sup> to form **8** in 70% yield. Cyclopropanation of **4** with diazomethane using transition metal catalysts was also investigated to obtain **7** directly. Use of PdCl<sub>2</sub>(PhCN)<sub>2</sub> resulted in the formation of **7** in low yield (23%) whereas Rh<sub>2</sub>(OAc)<sub>2</sub> did not catalyze the reaction. Removal of the *t*Boc group of **8** with trifluoroacetic acid (TFA) gave the desired product (**10**), which, without purification, was submitted to the manipulation of adenine ring construction to give the final product (**13**)<sup>18</sup> via **11** and **12** as shown in Scheme 2.

In conclusion, we have achieved the first synthesis of 2',3'-methano carbocyclic nucleoside (**13**) from ABH in ca. 12% total yield. We have found that **1** is more reactive than the cyclopentene (**4**) for both the



Scheme 2. (a) 5-Amino-4,6-dichloropyrimidine, *i*-Pr<sub>2</sub>NEt, *n*-BuOH, reflux, 24 h; (b) CH(OEt)<sub>3</sub>, 10N HCl, rt, 20 h; (c) NH<sub>3</sub>, MeOH, 50°C, 24 h (sealed tube)

1,3-dipolar cycloaddition with diazomethane and the cyclopropanation using PdCl<sub>2</sub>(PhCN)<sub>2</sub>. This might be attributable to factor 'X'<sup>19</sup> or staggering of allylic bond<sup>20</sup> as observed in the cycloaddition to the C=C bond of norbornene. Works on the antiviral evaluation of 13 and the synthesis of its guanine congener are in progress, and the results will be reported in due course.

## Acknowledgements

We wish to thank Kuraray Co., Ltd for providing us 2-azabicyclo[2.2.1]hept-5-en-3-one (ABH).

## References

1. Part ILV of Synthesis of nucleosides and their related compounds. For Part ILIV, see: Katagiri, N.; Morishita, Y.; Oosawa, U.; Yamaguchi, M. *Tetrahedron Lett.* **1999**, *40*, 6835–6840.
2. Okabe, M.; Sun, R.-C. *Tetrahedron Lett.* **1989**, *30*, 2203–2206.
3. Chang, H. S.; Bergmeier, S. C.; Frick, J. A.; Bathe, A.; Rapoport, H. *J. Org. Chem.* **1994**, *59*, 5336–5342.
4. Marquez, V. E.; Siddiqui, M. A.; Ezzitouni, A.; Russ, P.; Wang, J.; Wagner, R. W.; Matteucci, M. D. *J. Med. Chem.* **1996**, *39*, 3739–3747.
5. Altmann, K.-H.; Kesselring, R.; Francotte, E.; Rihs, G. *Tetrahedron Lett.* **1994**, *35*, 2331–2334.
6. Altmann, K.-H.; Imwinkelried, R.; Kesselring, R.; Rihs, G. *Tetrahedron Lett.* **1994**, *35*, 7625–7628.
7. (a) Vince, R.; Hua, M. *J. Med. Chem.* **1990**, *33*, 17–21. (b) Vince, R.; Brownell, J. *Biochem. Biophys. Res. Commun.* **1990**, *168*, 912 and references cited therein.
8. Katagiri, N.; Takebayashi, M.; Kokufuda, H.; Kaneko, C.; Kanehira, K.; Torihara, M. *J. Org. Chem.* **1997**, *62*, 1580–1581.
9. Toyota, A.; Habutani, C.; Katagiri, N.; Kaneko, C. *Tetrahedron Lett.* **1994**, *35*, 5665–5668.
10. Unpublished results.
11. An ethereal solution of diazomethane containing methanol was obtained from the treatment of *N*-methyl-*N*-nitroso-*p*-toluenesulfonylamide with sodium hydroxide in methanol–water whereas methanol free diazomethane–ether solution was prepared using carbitol instead of methanol.
12. Compound 2 (less polar): mp 123°C (dec.) (hexane–AcOEt). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 1.43 (9H, s), 1.80 (1H, dt, *J*=13.7, 8.4 Hz), 1.92 (1H, dt, *J*=13.7, 5.1 Hz), 2.40 (1H, br s), 3.35 (1H, br s), 3.58 (1H, br s), 3.82 (3H, s), 4.55 (1H, dd, *J*=18.6, 9.0 Hz), 4.70 (1H, dt, *J*=18.6, 2.9 Hz), 5.11 (1H, br s), 5.30 (1H, ddd, *J*=8.3, 5.4, 2.9 Hz). 3 (more polar): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 1.48 (9H, s), 1.92 (2H, m), 2.31 (1H, dd, *J*=6.3, 2.7 Hz), 2.83 (1H, m), 3.72 (3H, s), 4.39 (1H, dd, *J*=18.3, 8.4 Hz), 4.44 (1H, br s), 4.66 (1H, d, *J*=18.4 Hz), 4.93 (1H, br s), 5.41 (1H, br s).
13. Katagiri, N.; Matsuhashi, Y.; Kokufuda, H.; Takebayashi, M.; Kaneko, C. *Tetrahedron Lett.* **1997**, *38*, 1645–1648. The *exo*-selectivity would be due to pyramidarization [Williams, R. V.; Gadgil, V. R.; Garner, G. G.; Williams, J. D.; Vij, S. *Tetrahedron Lett.* **1999**, *40*, 2689–2690, and references cited therein] or Cieplak effect [Cieplack, A. S.; Tait, B. D.; Johnson, C. R. *J. Am. Chem. Soc.* **1989**, *111*, 8447–8462] as observed in the selectivity for the addition to a double bond of bicyclic compound.
14. Compound 4 was prepared in 54% yield by refluxing of 1 in methanol with catalytic amount of conc. hydrochloric acid for 4 h, mp 36°C.

15. Compound **5** (less polar): mp 143°C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 0.83 (1H, br d, J=11.3 Hz), 1.58 (9H, s), 1.85 (1H, dt, J=11.3, 1.5 Hz), 2.51–2.61 (1H, m), 2.63 (1H, br s), 4.23 (1H, dt, J=19.0, 3.4 Hz), 4.71 (1H, ddd, J=19.0, 9.7, 1.7 Hz), 5.06 (1H, t, J=1.5 Hz), 5.29–5.36 (1H, m). **6** (more polar): mp 148–150°C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): 0.83 (1H, br d, J=11.4 Hz), 1.53 (9H, s), 1.86 (1H, br d, J=11.4 Hz), 2.54–2.65 (1H, m), 3.47 (1H, br s), 4.23 (1H, dt, J=19.0, 4.2 Hz), 4.29 (1H, br s), 4.59 (1H, ddd, J=19.0, 9.8, 1.5 Hz), 5.28 (1H, br dd, J=7.1, 1.1 Hz).
16. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): 0.00 (1H, m, overlapped with TMS), 0.49 (1H, dt, J=8.3, 5.4 Hz), 1.34 (2H, m), 1.44 (10H, s and m), 1.78 (1H, dt, J=14.6, 7.3 Hz), 2.16 (1H, dt, J=8.8, 4.4 Hz), 2.80 (1H, br), 3.58 (1H, dd, J=10.3, 4.4 Hz), 3.70 (1H, dd, J=10.3, 3.9 Hz), 4.00 (1H, br), 5.90 (1H, d, NH).
17. Katagiri, N.; Muto, M.; Kaneko, C. *Tetrahedron Lett.* **1989**, *30*, 1645–1648.
18. Compound **13**: mp 215–216°C. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD): 0.44 (1H, dt, J=4.9, 3.9 Hz), 0.88 (1H, dt, J=5.3, 8.4 Hz), 1.81 (1H, dt, J=8.3, 4.4 Hz), 1.94 (1H, dt, J=8.3, 3.9 Hz), 2.07 (1H, dt, J=15.6, 7.8 Hz), 2.28 (1H, q, J=7.8 Hz), 3.18 (1H, dd, J=10.8, 7.8 Hz), 3.37 (1H, dd, J=10.8, 7.3 Hz), 4.91 (1H, d, J=6.8 Hz), 8.20 (1H, s), 8.36 (1H, s). Anal. calcd for C<sub>12</sub>H<sub>13</sub>N<sub>5</sub>O: C, 59.25; H, 5.39; N, 28.79. Found: C, 59.15; H, 5.50; N, 28.63.
19. Huisgen, R.; Ooms, P. H. J.; Mingin, M.; Allinger, N. L. *J. Am. Chem. Soc.* **1980**, *102*, 3951–3953.
20. Rondan, N. G.; Paddon-Row, M. N.; Caramella, P.; Mareda, J.; Mueller, P. H.; Houk, K. N. *J. Am. Chem. Soc.* **1982**, *104*, 4974–4976.